OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Oral Aripiprazole Open-Label Rollover Study
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2013-09-27
- Target Recruit Count
- 85
- Registration Number
- NCT01001702
- Locations
- 🇺🇦
Study site, Kiev, Ukraine
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2014-07-31
- Target Recruit Count
- 207
- Registration Number
- NCT00948090
- Locations
- 🇺🇸
UCSD Medical Center BMT Program, La Jolla, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2015-10-20
- Target Recruit Count
- 459
- Registration Number
- NCT00905307
- Locations
- 🇷🇸
Study Site (1), Belgrade, Serbia
🇷🇸Study Site (2), Belgrade, Serbia
🇷🇴Study Site (3), Bucuresti, Romania
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2017-04-17
- Target Recruit Count
- 84
- Registration Number
- NCT00874497
- Locations
- 🇺🇸
Los Angeles Biomedical Institute, Torrance, California, United States
🇺🇸Pulmonary Disease Specialist/PDS Research, Kissimmee, Florida, United States
🇺🇸Texas Institute of Chest and Sleep Disorders, PA, Houston, Texas, United States
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
- Conditions
- SchizophreniaSchizoaffective DisorderBipolar I DisorderMetabolic Syndrome
- Interventions
- Drug: Oanzapine, risperidone, or quetiapine
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2013-12-02
- Target Recruit Count
- 64
- Registration Number
- NCT00857818
- Locations
- 🇨🇦
Local Institution, Quebec, Canada
Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
- Conditions
- Schizophrenia
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2010-05-07
- Target Recruit Count
- 15
- Registration Number
- NCT00805454
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2016-02-29
- Target Recruit Count
- 850
- Registration Number
- NCT00797966
- Locations
- 🇺🇸
Florida Clinical Research Center, LLC, Bradenton, Florida, United States
🇺🇸Vince & Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸Synergy Clinical Research Center, National City, California, United States
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2014-11-26
- Target Recruit Count
- 1081
- Registration Number
- NCT00731549
- Locations
- 🇺🇸
Study Site, San Diego, California, United States
Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 690
- Registration Number
- NCT00712686
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: Placebo tabletsDrug: Placebo depot
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2013-08-14
- Target Recruit Count
- 937
- Registration Number
- NCT00706654